FAQs
Metabolite profiling is part of an emerging field of chemical and clinical analysis that identifies and measures changes in important small molecule metabolites—also known as biomarkers—found in blood, urine, saliva, tears, and spinal fluid. Matrix-Bio is working to turn patented metabolite profiling methods into specific diagnostic tests so that through a simple blood test it will be possible to detect disease in its very early stages with a high degree of accuracy. Metabolite profiling can be used for cancer screening, and to monitor the recurrence of cancer or how a patient is responding to treatment. Metabolite profiling offers great promise to physicians and patients.
Matrix-Bio has developed a unique, patent-pending technology platform that utilizes metabolite profiling to detect cancer. The VeraMarker™ metabolite profiling technology platform is the basis for a new family of cancer tests that offer the potential for more sensitive and specific detection of cancer, including identifying cancer recurrence, monitoring cancer treatment, and predicting a patient’s response to certain cancer treatments. Matrix-Bio is developing cancer diagnostics tests utilizing the VeraMarker™ technology platform for liver and colon cancer.
Metabolite profiling has three distinct advantages, which makes it highly effective in the accurate and early diagnosis of cancer:

  • Compared to RNA and DNA, metabolites are more diagnostic and easier to detect.
  • Compared to circulating tumor cells, metabolites have fewer false negatives.
  • Compared to proteins (proteomics), metabolites are more robust and easier to multiplex.

In a word: accuracy. Matrix-Bio’s metabolite profiling diagnostic tests can be used to identify the presence or absence of liver and colon cancer with a much higher degree of sensitivity and specificity than current tests. Accuracy and ability of Matrix-Bio’s liver and colon cancer diagnostic tests to detect cancer months and even years before current tests is an exciting, potentially life-saving advancement.
Matrix-Bio’s simple blood tests may revolutionize how patients are screened for colon cancer and how physicians monitor patients for colon cancer recurrence and track the effects of therapy. Using metabolite profiling, Matrix-Bio is able to identify and measure changes within a patient’s specific sets of biomarkers, and in so doing, accurately and reliably detect early stage colon cancer as well as the recurrence of colon cancer.
Matrix-Bio is currently developing a suite of colon cancer diagnostic tests using the VeraMarker™ metabolite profiling technology platform that will provide more accurate, early diagnosis of colon cancer:

VeraMarker™ CCM (Colon Cancer Monitoring) Test
VeraMarker™ CCS (Colon Cancer Screening) Test

The colon cancer treatment monitoring test will follow.

Matrix-Bio is working to bring its cancer diagnostic tests to market. We invite you to register so that we can provide important updates on the availability of our tests. Register Here

We are also looking for oncologists interested in helping us advance our portfolio of liver and colon cancer diagnostic tests. We invite you to email Matrix-Bio CEO Dr. Eric Beier for more information.

Although Matrix-Bio’s tests in the most advanced stages of development are for breast and colon cancer, our patented VeraMarker™ technology platform using metabolite profiling can be leveraged to detect other forms of cancer. This is good news for patients, physicians, and others who want better, more accurate tests for deadly cancers.
Matrix-Bio’s simple blood tests may revolutionize how patients are screened for liver cancer and how patients with hepatitis C and hepatitis B with cirrhosis are monitored. These tests may also change how physicians track the effects of therapy. Using metabolite profiling, Matrix-Bio is able to identify and measure changes within a patient’s specific sets of biomarkers, and in so doing, accurately and reliably detect early stage liver cancer as well monitor those at high risk of liver cancer.
Matrix-Bio is currently liver cancer diagnostic tests using the VeraMarker™ metabolite profiling technology platform that will provide more accurate, early diagnosis of liver cancer, thereby increasing the treatment options available to patients and improving long-term prognosis. The test can also be used to monitor patients who are at high risk of liver cancer due to hepatitis C and hepatitis B with cirrhosis. These individuals have up to a five percent chance of developing liver cancer and can benefit from early diagnosis.